Molecular Partners(MOLN)
Schlieren-Zurich, SwitzerlandBiotechnology
Focus: Molecular Partners is a publicly traded Swiss biotech specializing in DARPin® technology-derived biologics across oncology, infectious diseases, and ophthalmology. The company operates as a mid-cap biotech with a diversified pipeline of 16 clinical programs.
Profile data last refreshed 14h ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Open Jobs
0
About Molecular Partners
AI assessmentNot HiringNo open roles listed right now. Follow Molecular Partners to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Mid-stage
2 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
MP0317, a tri-specific fibroblast activation protein
Advanced Malignant Solid TumorClinical Trials (1)
NCT05098405First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors
Phase 1Help build intelligence for Molecular Partners
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.